This product is a paramagnetic contrast agent used for magnetic resonance imaging. After entering the body, it can shorten the T1 and T2 relaxation times of protons in tissues, thereby enhancing image clarity and contrast.

Extract from the above information

Glimepiride is an oral sulfonylurea hypoglycemic drug that works mainly by stimulating the release of insulin from pancreatic beta cells and has an extrapancreatic hypoglycemic effect. 1. Insulin release: regulates insulin secretion by closing the ATP-sensitive potassium ion channel of the pancreatic beta cell membrane, inducing beta cell membrane depolarization, opening calcium ion channels to cause calcium ion influx, and promoting insulin release. 2. Extrapancreatic activity: improves the sensitivity of peripheral tissues to insulin, reduces the output of glucose by the liver, and increases the number of glucose transfer molecules in the plasma membrane of muscle and fat cells, thereby stimulating glucose uptake. 3. The minimum effective oral dose for healthy people is about 0.6 mg, and the effect is dose-dependent and repeatable.

This preparation enhances the proton signal in water in aqueous solution and is effective as an oral contrast agent for magnetic resonance imaging. Experiments on rats have shown that the contrast effect of the gastrointestinal tract is enhanced after a certain amount of ammonium ferric citrate solution (1-3mmol/L) is given, and the gastrointestinal cavity can be identified from the adjacent soft tissue. Experiments on rabbits have shown that ammonium ferric citrate (2mmol/L) can satisfactorily enhance the signal contrast on spin echo (SE) sequence T1W and T2W images. The results of acute toxicity experiments have shown that when the maximum dose of ammonium ferric citrate effervescent powder is 2000mg/kg for rats and dogs, no obvious toxic reactions are observed except for fecal changes (such as softened or watery stools).

This preparation enhances the proton signal in water in aqueous solution, which shows that it is effective as an oral contrast agent for magnetic resonance imaging. The results of rat experiments show that the contrast effect of the gastrointestinal tract is enhanced after a certain amount of ammonium ferric citrate solution (1-3mmol/L) is given, and the gastrointestinal cavity can be identified from the adjacent soft tissue. Rabbit experiments show that ammonium ferric citrate (2mmol/L) can satisfactorily enhance the signal contrast on the T1W and T2W images of the spin echo (SE) sequence. Referring to foreign literature, the results of acute toxicity experiments show that when the maximum dose of ammonium ferric citrate effervescent powder is 2000mg/kg for rats and dogs, no obvious toxic reactions are observed except for fecal changes (such as softened or watery stools).